<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Clin Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Int J Clin Oncol</journal-id><journal-title-group><journal-title>International Journal of Clinical Oncology</journal-title></journal-title-group><issn pub-type="ppub">1341-9625</issn><issn pub-type="epub">1437-7772</issn><publisher><publisher-name>Springer Nature Singapore</publisher-name><publisher-loc>Singapore</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39681749</article-id><article-id pub-id-type="pmc">PMC11785594</article-id>
<article-id pub-id-type="publisher-id">2672</article-id><article-id pub-id-type="doi">10.1007/s10147-024-02672-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Treatment-related skin reactions in enfortumab vedotin as a surrogate marker of survival and treatment response</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6239-2917</contrib-id><name><surname>Nagayama</surname><given-names>Jun</given-names></name><address><email>j.nagayama@med.nagoya-u.ac.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Inoue</surname><given-names>Satoshi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sai</surname><given-names>Hiroki</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hayakawa</surname><given-names>Akira</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Yuguchi</surname><given-names>Yuri</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Suzuki</surname><given-names>Tomohide</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Matsui</surname><given-names>Hirotaka</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Yuba</surname><given-names>Takuma</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Morishita</surname><given-names>Koya</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Akamatsu</surname><given-names>Shusuke</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04chrp450</institution-id><institution-id institution-id-type="GRID">grid.27476.30</institution-id><institution-id institution-id-type="ISNI">0000 0001 0943 978X</institution-id><institution>Department of Urology, </institution><institution>Nagoya University Graduate School of Medicine, </institution></institution-wrap>65 Tsuruma-cho, Showa-Ku, Nagoya, Aichi 466-8550 Japan </aff><aff id="Aff2"><label>2</label>Department of Urology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03k36hk88</institution-id><institution-id institution-id-type="GRID">grid.417360.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1772 4873</institution-id><institution>Department of Urology, </institution><institution>Yokkaichi Municipal Hospital, </institution></institution-wrap>Yokkaichi, Japan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03j56s085</institution-id><institution-id institution-id-type="GRID">grid.414470.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0377 9435</institution-id><institution>Department of Urology, </institution><institution>Chukyo Hospital, </institution></institution-wrap>Nagoya, Japan </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04ftw3n55</institution-id><institution-id institution-id-type="GRID">grid.410840.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 7902</institution-id><institution>Department of Urology, </institution><institution>Nagoya Medical Center, </institution></institution-wrap>Nagoya, Japan </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03h3tds63</institution-id><institution-id institution-id-type="GRID">grid.417241.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1772 7556</institution-id><institution>Department of Urology, </institution><institution>Toyohashi Municipal Hospital, </institution></institution-wrap>Toyohashi, Japan </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00vzw9736</institution-id><institution-id institution-id-type="GRID">grid.415024.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 0642 0647</institution-id><institution>Department of Urology, </institution><institution>Kariya Toyota General Hospital, </institution></institution-wrap>Kariya, Japan </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0266t0867</institution-id><institution-id institution-id-type="GRID">grid.416762.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 1772 7492</institution-id><institution>Department of Urology, </institution><institution>Komaki Municipal Hospital, </institution></institution-wrap>Komaki, Japan </aff></contrib-group><pub-date pub-type="epub"><day>16</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>16</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>30</volume><issue>2</issue><fpage>267</fpage><lpage>276</lpage><history><date date-type="received"><day>11</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>26</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Treatment-related skin reactions (TRSRs) induced by enfortumab vedotin (EV) targeting nectin-4 are among the most common adverse events. However, their association with survival and treatment response is poorly understood.</p></sec><sec><title>Methods</title><p id="Par2">We retrospectively identified patients who received EV from December 2021 to April 2023 at Nagoya University Hospital and its affiliated facilities and extracted clinical data from their medical records. We evaluated cancer-specific survival (CSS) and progression-free survival (PFS) as survival outcomes and overall response rate (ORR) and disease control rate (DCR) as treatment responses between patients with and without TRSRs.</p></sec><sec><title>Results</title><p id="Par3">In total, 67 eligible patients were identified. Thirty-four patients experienced TRSRs, and the remaining 33 did not experience TRSRs. The median follow-up period was 8 months. Patients in the TRSRs group demonstrated significantly longer median CSS (15 vs. 8 months; <italic>p</italic> = 0.003) and median PFS (10 vs. 5 months;<italic> p</italic> &#x0003c; 0.001) than the non-TRSRs. Regarding treatment response, the patients in the TRSRs group showed a favorable, albeit nonsignificant, treatment response trend compared with those in the non-TRSRs group (ORR, 73.5% vs. 51.5%; <italic>p</italic> = 0.107; DCR, 91.2 % vs. 81.8%; <italic>p =</italic> 0.444).</p></sec><sec><title>Conclusions</title><p id="Par4">Patients with TRSRs demonstrated more prolonged survival and superior treatment responses to EV treatment. The role of TRSR as a surrogate marker of EV&#x02019;s efficacy should be further explored in prospective and sufficiently powered studies.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s10147-024-02672-3.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Enfortumab vedotin</kwd><kwd>Skin rash</kwd><kwd>Adverse effects</kwd><kwd>Bladder cancer</kwd><kwd>Urothelial carcinoma</kwd></kwd-group><funding-group><award-group><funding-source><institution>Nagoya University</institution></funding-source></award-group><open-access><p>Open Access funding provided by Nagoya University.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Japan Society of Clinical Oncology 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">In Japan, enfortumab vedotin (EV) was approved in November 2021 as a third-line therapy for patients with advanced urothelial carcinoma (UC) that is refractory to prior platinum-based chemotherapy and immune-checkpoint inhibitors (ICIs) such as programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) inhibitors [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. EV is a novel antibody-drug conjugate (ADC) targeting nectin-4 expressed in patients with UC comprising an anti-nectin-4 antibody, protease-cleavable linker, and microtubule-disrupting agent monomethyl auristatin E (MMAE) [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. These elements work sequentially and specifically in cells expressing nectin-4, consequently inducing apoptosis and cell death [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par6">Nectin-4 is a Ca<sup>2+</sup>-independent immunoglobulin-like cell-cell adhesion molecule generally expressed in human epidermal keratinocytes and skin appendages [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. The positive expression rate in normal skin exceeded 90% [<xref ref-type="bibr" rid="CR6">6</xref>]. Therefore, treatment-related skin reactions (TRSRs) are frequently occurring adverse events (AEs) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Meanwhile, nectin-4 is also expressed in several carcinomas and is associated with tumor progression [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Especially in UC, high-frequency nectin-4 expression is observed across the disease spectrum (87% in the bladder, 66% in the upper urinary tract, and 92% in metastatic sites) [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par7">Despite high expression of nectin-4 in the skin, TRSRs are observed in only about 55% of patients, suggesting that susceptibility to TRSRs varies even among those expressing nectin-4 [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. We hypothesized that the disparities in susceptibility to TRSRs may also impact UC&#x02019;s response to EV. According to this theory, TRSRs could serve as a significant predictive indicator of EV; [<xref ref-type="bibr" rid="CR11">11</xref>] however, the association between TRSRs and treatment response or survival benefits has not been fully discussed.</p><p id="Par8">Therefore, we evaluated how TRSRs to EV are associated with treatment response and survival outcomes in patients with advanced UC receiving EV as the third- or later-line treatment.</p></sec><sec id="Sec2"><title>Patients and methods</title><sec id="Sec3"><title>Patient population</title><p id="Par9">This retrospective multicenter collaborative study was conducted as part of the overarching MEGUMI (MEidai GenitoUrinary Mega Investigation) project. Nagoya University Hospital and its affiliated hospitals conduct clinical research and share a research database. The entire study was centrally approved by the institutional review board of Nagoya University Graduate School of Medicine (approval number: 2016-0474-5). Individual IRB approval at the affiliate hospitals was officially waived.</p><p id="Par10">We identified 78 patients who received EV between December 2021 and April 2023 at Nagoya University Hospital and seven affiliated hospitals. All the enrolled patients underwent radiographical evaluation at least once after EV initiation. We excluded those with no evaluable metastatic sites and Eastern Cooperative Oncology Group performance statuses (ECOG PS) &#x02265;3. The remaining 67 patients were classified into two groups based on the TRSR occurrence. The flowchart explaining patient inclusion is shown in Figure <xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>Enrolled patients&#x02019; inclusion criteria</p></caption><graphic xlink:href="10147_2024_2672_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec4"><title>Treatment and evaluation</title><p id="Par11">EV was administered at 1.25mg/kg on days 1, 8, and 15 of a 28-day cycle. Each physician&#x02019;s decision based on the patient&#x02019;s status allowed an initial dose reduction at EV initiation. The physicians also determined if treatment would be interrupted or discontinued based on the recommended dosing criteria of EV, patients&#x02019; general status, physical findings, radiological findings, and laboratory data at each visit. All enrolled patients received at least one radiological evaluation by computed tomography, combined with magnetic resonance imaging in some cases. The radiological assessment interval depended on physicians&#x02019; policy, which ranged from one to three months. The treatment response was assessed based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 [<xref ref-type="bibr" rid="CR12">12</xref>].</p></sec><sec id="Sec5"><title>Data extraction</title><p id="Par12">We carefully examined the medical records of the enrolled patients and gathered detailed patient demographic information, including age; sex; ECOG PS; comorbidities; primary and metastatic tumor locations; details of prior treatments; treatment details of EV, such as treatment cycles, dose reduction, and treatment discontinuation due to treatment-related adverse events (TRAEs); laboratory data; and pathology data. In addition, we computed the Bellmunt risk score using the patients&#x02019; demographic details [<xref ref-type="bibr" rid="CR13">13</xref>]. TRSRs were assessed for onset time, grade, dose reduction and treatment discontinuation due to TRSRs. We also evaluated the treatment for TRSRs, and skin response manifestations. All TRAEs including TRSRs were graded according to the Common Terminology for Adverse Events (CTCAE) version 5.0 [<xref ref-type="bibr" rid="CR14">14</xref>].</p></sec><sec id="Sec6"><title>Outcome measures</title><p id="Par13">First, we investigated the relationship between the TRSR occurrences and survival outcomes, in which cancer-specific survival (CSS) and progression-free survival (PFS) were evaluated. CSS was defined as the duration from the EV initiation to cancer-specific death. PFS was defined as the duration from the EV initiation to confirmation of disease progression or death.</p><p id="Par14">Then, we assessed the relationship between the TRSRs and treatment response. The best response was defined according to RECIST. We calculated the overall response rate (ORR) and disease control rate (DCR) based on the data. ORR was the sum of the partial response (PR) rate and complete response (CR) rate, and DCR also included those with stable disease (SD).</p></sec><sec id="Sec7"><title>Statistical analysis</title><p id="Par15">Chi-square and Mann&#x02013;Whitney U tests were used to compare categorical and continuous variables and evaluate the patients&#x02019; demographic data. Categorical variables are reported as frequencies and percentages. Furthermore, continuous variables are reported as averages with standard deviations (SD) for normal distribution and medians with interquartile ranges (IQR) for non-normal distribution, respectively.</p><p id="Par16">We estimated CSS and PFS used the Kaplan&#x02013;Meier method and between-group comparisons, using the log-rank test to calculate the groups&#x02019; median survival and 95 % confidence interval (CI). Furthermore, the Chi-squared test compared ORR and DCR between the two groups.</p><p id="Par17">Finally, multivariable Cox proportional hazard model analysis was performed to assess the prognostic factors for CSS and PFS, including age, sex, ECOG PS, Bellmunt risk score, diabetes, primary site, metastatic site, liver metastasis, line of therapy, most recent systemic therapy before EV, dose reduction/treatment discontinuation, prior radical therapy, and TRSRs.</p><p id="Par18">All statistical analyses were performed using the EZR software (Saitama Medical Center, Jichi Medical University, Saitama, Japan), a graphical user interface for R software (R Foundation for Statistical Computing, Vienna, Austria) [<xref ref-type="bibr" rid="CR15">15</xref>]. All <italic>p-</italic>values are two-sided, and <italic>p</italic> &#x0003c;0.05 was considered statistically significant.</p></sec></sec><sec id="Sec8"><title>Results</title><sec id="Sec9"><title>TRSRs</title><p id="Par19">In the present study, TRSRs occurred in 50.7% of EV. Regarding TRSR type, erythema&#x02014;including erythema multiform&#x02014;occurred in 32.4%, followed by bullous dermatitis in 11.8%. Eighty percent of TRSRs occurred within three cycles of EV treatment, and most were low-grade (Grade 1&#x02013;2). TRSRs affected dose intensity, and 50% (17/34) of the patients with TRSRs experienced at least either dose reduction or treatment discontinuation. Moreover, 17.6% (3/17) and 41.2% (7/17) of these patients experienced two-step dose reduction and treatment discontinuation, respectively. The details on TRSRs are shown in Table <xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Detailed treatment-related skin reaction data</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variables</th><th align="left">TRSRs (n = 34)</th></tr></thead><tbody><tr><td align="left" colspan="2">Onset time of TRSRs, no. (%)</td></tr><tr><td align="left">&#x000a0;1&#x02013;3 cycles</td><td align="left">27 (79.4)</td></tr><tr><td align="left">&#x000a0;&#x02265;4 cycles</td><td align="left">7 (20.6)</td></tr><tr><td align="left" colspan="2">CTCAE grade, no. (%)</td></tr><tr><td align="left">&#x000a0;1&#x02013;2</td><td align="left">27 (79.4)</td></tr><tr><td align="left">&#x000a0;3</td><td align="left">7 (20.6)</td></tr><tr><td align="left" colspan="2">Type of TRSRs, no. (%)</td></tr><tr><td align="left">&#x000a0;Erythema</td><td align="left">9 (26.5)</td></tr><tr><td align="left">&#x000a0;Erythema multiforme</td><td align="left">2 (5.9)</td></tr><tr><td align="left">&#x000a0;Bullous dermatitis</td><td align="left">4 (11.8)</td></tr><tr><td align="left">&#x000a0;Rash with details unknown</td><td align="left">19 (55.9)</td></tr><tr><td align="left">&#x000a0;Dose reduction of EV due to TRSRs, no. (%)</td><td align="left">12 (35.3)</td></tr><tr><td align="left">&#x000a0;One-step dose reduction (1.0 mg/kg), no. (%)</td><td align="left">9</td></tr><tr><td align="left">&#x000a0;Two-step dose reduction (0.75 mg/kg), no. (%)</td><td align="left">3</td></tr><tr><td align="left">&#x000a0;Discontinuation EV due to TRSRs, no. (%)</td><td align="left">7 (20.6)</td></tr><tr><td align="left" colspan="2">Treatment, no. (%)</td></tr><tr><td align="left">&#x000a0;Topical corticosteroid</td><td align="left">28 (82.4)</td></tr><tr><td align="left">&#x000a0;Systemic corticosteroid</td><td align="left">3 (8.8)</td></tr><tr><td align="left">&#x000a0;Antihistamine</td><td align="left">11(32.4)</td></tr></tbody></table><table-wrap-foot><p><italic>CTCAE</italic> Common Terminology Criteria for Adverse Events, <italic>EV</italic> enfortumab vedotin, <italic>TRSRs</italic> treatment-related skin reactions</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec10"><title>Patients&#x02019; characteristics</title><p id="Par20">Sixty-seven patients were identified; their characteristics are shown in Table <xref rid="Tab2" ref-type="table">2</xref>. At baseline, there were no remarkable differences in the distribution of patients&#x02019; ages, sex, and ECOG PSs between the TRSRs and non-TRSRs groups. The variance among the two groups was present in the Bellumunt risk score (&#x02265;2: 32.4% vs. 51.5% in the TRSRs and non-TRSRs groups) and primary site (bladder: 52.9% vs. 63.6%; upper urinary tract: 41.2% vs. 21.2%; bladder and upper urinary tract: 5.9% vs. 15.2%); however, these differences did not rise to the level of statistical significance. Regarding laboratory data, only hemoglobin level was higher in the TRSR group than in the non-TRSRs group, whereas no differences were noted in the other variables (Supplementary Table 1). Patients in the non-TRSRs group were more likely to have received chemotherapy (8.8% vs. 27.3%; <italic>p</italic> = 0.099) and received more chemotherapy cycles; however, the median cycles were similar between the groups (median 4 cycles; IQR 2&#x02013;4 cycles vs. median 4 cycles; IQR 3.75&#x02013;6 cycles; <italic>p</italic> = 0.041). Prior ICI reception was also similar between the two groups. Moreover, the TRSRs group received more EV cycles than the non-TRSRs group (median 6 cycles; IQR 4&#x02013;11 cycles vs. median 4 cycles; IQR 2&#x02013;6 cycles; <italic>p</italic> = 0.004).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Patients&#x02019; characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variables</th><th align="left">TRSRs (n = 34)</th><th align="left">Non-TRSRs (n = 33)</th><th align="left"><italic>p</italic></th></tr></thead><tbody><tr><td align="left">Age median, years (IQR)</td><td align="left">71.5 (64.75&#x02013;75.75)</td><td align="left">73.0 (68.0&#x02013;75.0)</td><td char="." align="char">0.546</td></tr><tr><td align="left" colspan="4">Sex, no. (%)</td></tr><tr><td align="left">&#x000a0;Male</td><td align="left">26 (76.5)</td><td align="left">27 (81.8)</td><td char="." align="char">0.812</td></tr><tr><td align="left">&#x000a0;Female</td><td align="left">8 (23.5)</td><td align="left">6 (18.2)</td><td char="." align="char"/></tr><tr><td align="left" colspan="4">ECOG PS, no. (%)</td></tr><tr><td align="left">&#x000a0;0&#x02013;1</td><td align="left">32 (94.1)</td><td align="left">29 (87.9)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;2</td><td align="left">2 (5.9)</td><td align="left">4 (12.1)</td><td char="." align="char">0.641</td></tr><tr><td align="left" colspan="4">Bellmunt risk score<sup>a</sup>, no. (%)</td></tr><tr><td align="left">&#x000a0;0&#x02013;1</td><td align="left">23 (67.6)</td><td align="left">16 (48.5)</td><td char="." align="char">0.180</td></tr><tr><td align="left">&#x000a0;&#x02265;2</td><td align="left">11 (32.4)</td><td align="left">17 (51.5)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Diabetes, no. (%)</td><td align="left">10 (29.4)</td><td align="left">5 (15.2)</td><td char="." align="char">0.268</td></tr><tr><td align="left" colspan="4">Primary site, no. (%)</td></tr><tr><td align="left">&#x000a0;Bladder</td><td align="left">18 (52.9)</td><td align="left">21 (63.6)</td><td char="." align="char">0.147</td></tr><tr><td align="left">&#x000a0;Upper urinary tract</td><td align="left">14 (41.2)</td><td align="left">7 (21.2)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Bladder + upper urinary tract</td><td align="left">2 (5.9)</td><td align="left">5 (15.2)</td><td char="." align="char"/></tr><tr><td align="left" colspan="4">Metastatic site, no. (%)</td></tr><tr><td align="left">&#x000a0;Lymph node only</td><td align="left">9 (26.5)</td><td align="left">10 (30.3)</td><td char="." align="char">0.939</td></tr><tr><td align="left">&#x000a0;Visceral</td><td align="left">25 (73.5)</td><td align="left">23 (69.7)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Liver</td><td align="left">10 (29.4)</td><td align="left">8 (24.2)</td><td char="." align="char">0.840</td></tr><tr><td align="left" colspan="4">Line of therapy, no. (%)</td></tr><tr><td align="left">&#x000a0;3</td><td align="left">26 (76.5)</td><td align="left">22 (66.7)</td><td char="." align="char">0.536</td></tr><tr><td align="left">&#x000a0;&#x02265;4</td><td align="left">8 (23.5)</td><td align="left">11 (33.3)</td><td char="." align="char"/></tr><tr><td align="left" colspan="4">The most recent systemic therapy before EV, no. (%)</td></tr><tr><td align="left">&#x000a0;ICI</td><td align="left">31 (91.2)</td><td align="left">24 (72.7)</td><td char="." align="char">0.099</td></tr><tr><td align="left">&#x000a0;Chemotherapy</td><td align="left">3 (8.8)</td><td align="left">9 (27.3)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Prior chemotherapy, cycles (IQR)</td><td align="left">4 (2&#x02013;4)</td><td align="left">4 (3.75&#x02013;6)</td><td char="." align="char"><bold>0.041</bold></td></tr><tr><td align="left">&#x000a0;Prior ICI, cycles (IQR)</td><td align="left">6 (4&#x02013;12)</td><td align="left">5 (4&#x02013;12)</td><td char="." align="char">0.670</td></tr><tr><td align="left">&#x000a0;Duration of prior therapy to EV, months (IQR)</td><td align="left">0 (0&#x02013;1)</td><td align="left">0 (0&#x02013;1)</td><td char="." align="char">0.611</td></tr><tr><td align="left">&#x000a0;EV, cycles (IQR)</td><td align="left">6 (4&#x02013;11)</td><td align="left">4 (2&#x02013;6)</td><td char="." align="char"><bold>0.004</bold></td></tr><tr><td align="left">&#x000a0;Dose reduction due to TRAEs, no. (%)</td><td align="left">12 (35.3)</td><td align="left">5 (15.2)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;One-step reduction (1.0mg/kg)</td><td align="left">9</td><td align="left">4</td><td char="." align="char">0.107</td></tr><tr><td align="left">&#x000a0;Two-step reduction (0.75mg/kg)</td><td align="left">3</td><td align="left">1</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Discontinuation due to TRAEs, no. (%)</td><td align="left">7 (20.6)</td><td align="left">3 (9.1)</td><td char="." align="char">0.328</td></tr><tr><td align="left" colspan="4">Prior radical therapy, no. (%)</td></tr><tr><td align="left">&#x000a0;Yes</td><td align="left">21 (61.8)</td><td align="left">19 (57.6)</td><td char="." align="char">0.920</td></tr><tr><td align="left">&#x000a0;No</td><td align="left">13 (38.2)</td><td align="left">14 (42.4)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Variant histology, no. (%)</td><td align="left">1 (4.2)</td><td align="left">2 (7.7)</td><td char="." align="char">1.000</td></tr></tbody></table><table-wrap-foot><p><italic>IQR</italic> interquartile range, <italic>ECOG PS</italic> Eastern Cooperative Oncology Group performance status, <italic>EV</italic> enfortumab vedotin, <italic>ICI</italic> immune-checkpoint inhibitor, <italic>TRAEs</italic> treatment-related adverse events</p><p><sup>a</sup>Bellmunt risk score-liver metastases, hemoglobin level &#x0003c; 10g/dL, and ECOG PS &#x0003e; 0 are the factors; every point is added for each factor</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Survival and treatment response in comparison with and without TRSRs</title><p id="Par21">In the overall cohort, the median follow-up was 8 months (IQR: 5&#x02013;12), and the median CSS and PFS were 13 (95% CI: 10&#x02013;15) and 7 months (95% CI: 5&#x02013;9), respectively. The TRSRs group demonstrated significantly longer median CSS compared to the non-TRSRs group (15 months [95% CI: 12&#x02013;not available (NA)] vs. 8 months [95%CI: 7&#x02013;13]; <italic>p =</italic> 0.003). Moreover, the TRSRs group also showed significantly longer median PFS (10 months [95% CI: 7&#x02013;NA] vs. 5 months [95%CI: 3&#x02013;6];<italic> p</italic>&#x0003c;0.001). The Kaplan&#x02013;Meier curves for CSS and PFS are shown in Figure <xref rid="Fig2" ref-type="fig">2</xref>. No patients demonstrated a CR. The TRSRs group showed higher ORR and DCR. However, there was no statistical significance between-group differences (ORR: 73.5% vs. 51.5%; <italic>p</italic> = 0.107, DCR: 81.8% vs. 91.2%; <italic>p =</italic> 0.444; Table <xref rid="Tab3" ref-type="table">3</xref>). Multivariable Cox proportional hazard analysis was also performed for survival outcomes. TRSRs were shown as a favorable prognostic factor in CSS and PFS (CSS, HR 0.45 [95% CI, 0.20, 1.05]; <italic>p</italic> = 0.064; PFS, HR 0.48 [95% CI, 0.24, 0.96];<italic> p</italic> = 0.039), although no significant difference was found by a slight margin in CSS. These results are shown in Table <xref rid="Tab4" ref-type="table">4</xref>.<fig id="Fig2"><label>Fig. 2</label><caption><p>Kaplan&#x02013;Meier curves showing the comparison of CSS and PFS between patients with and without TRSRs</p></caption><graphic xlink:href="10147_2024_2672_Fig2_HTML" id="MO2"/></fig><table-wrap id="Tab3"><label>Table 3</label><caption><p>Comparison of treatment response between the TRSR group and non-TRSR group</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variables</th><th align="left">Overall (n = 67)</th><th align="left"/><th align="left"/></tr></thead><tbody><tr><td align="left" colspan="4">Best response, no (%)</td></tr><tr><td align="left">&#x000a0;CR</td><td align="left">0 (0.0)</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;PR</td><td align="left">42 (62.7)</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;SD</td><td align="left">16 (23.9)</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;PD</td><td align="left">9 (13.4)</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;ORR, %</td><td align="left">62.7</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;DCR, %</td><td align="left">86.6</td><td align="left"/><td align="left"/></tr><tr><td align="left">Variables</td><td align="left">TRSRs (n = 34)</td><td align="left">Non-TRSRs (n = 33)</td><td align="left"><italic>p</italic></td></tr><tr><td align="left" colspan="4">Best response, no (%)</td></tr><tr><td align="left">&#x000a0;CR</td><td align="left">0 (0.0)</td><td align="left">0 (0.0)</td><td align="left"/></tr><tr><td align="left">&#x000a0;PR</td><td align="left">25(73.5)</td><td align="left">17(51.5)</td><td align="left"/></tr><tr><td align="left">&#x000a0;SD</td><td align="left">6 (17.6)</td><td align="left">10(30.3)</td><td align="left"/></tr><tr><td align="left">&#x000a0;PD</td><td align="left">3 (8.8)</td><td align="left">6 (18.2)</td><td align="left"/></tr><tr><td align="left">&#x000a0;ORR, %</td><td align="left">73.5</td><td align="left">51.5</td><td align="left">0.107</td></tr><tr><td align="left">&#x000a0;DCR, %</td><td align="left">91.2</td><td align="left">81.8</td><td align="left">0.444</td></tr></tbody></table><table-wrap-foot><p><italic>CR</italic> complete response, <italic>PR</italic> partial response, <italic>SD</italic> stable disease, <italic>PD</italic> progressive disease, <italic>ORR</italic> overall response rate, <italic>DCR</italic> disease control rate, <italic>TRSRs</italic> treatment-related skin reactions</p></table-wrap-foot></table-wrap><table-wrap id="Tab4"><label>Table 4</label><caption><p>Univariate and multivariable Cox proportional hazard model analysis for CSS and PFS</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Univariate (HR, 95% CI)</th><th align="left">p value</th><th align="left">Multivariable (HR, 95% CI)</th><th align="left">p value</th></tr></thead><tbody><tr><td align="left" colspan="5"><italic>CSS</italic></td></tr><tr><td align="left" colspan="5">Age</td></tr><tr><td align="left">&#x000a0;&#x02265;72 vs. &#x0003c;72</td><td align="left">2.06 (0.94&#x02013;4.50)</td><td char="." align="char">0.071</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left" colspan="5">Sex</td></tr><tr><td align="left">&#x000a0;Male vs. female</td><td align="left">0.87 (0.35&#x02013;2.15)</td><td char="." align="char">0.764</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left" colspan="5">ECOG PS</td></tr><tr><td align="left">&#x000a0;0&#x02013;1 vs. 2</td><td align="left">2.60 (0.98&#x02013;6.90)</td><td char="." align="char">0.054</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left" colspan="5">Bellmunt risk score<sup>a</sup></td></tr><tr><td align="left">&#x000a0;0&#x02013;1 vs. &#x02265;2</td><td align="left">1.64 (0.79&#x02013;3.41)</td><td char="." align="char">0.183</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Diabetes</td><td align="left"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;No vs. yes</td><td align="left">1.60 (0.68&#x02013;3.76)</td><td char="." align="char">0.287</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left" colspan="5">Primary site</td></tr><tr><td align="left" colspan="5">&#x000a0;Bladder (ref)</td></tr><tr><td align="left">&#x000a0;&#x000a0;Upper urinary tract</td><td align="left">0.92 (0.39&#x02013;2.18)</td><td char="." align="char">0.851</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;&#x000a0;Bladder + upper urinary tract</td><td align="left">1.74 (0.63&#x02013;4.76)</td><td char="." align="char">0.285</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left" colspan="5">Metastatic site</td></tr><tr><td align="left">&#x000a0;LN vs. visceral</td><td align="left">0.54 (0.25&#x02013;1.18)</td><td char="." align="char">0.121</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left" colspan="5">Liver metastasis</td></tr><tr><td align="left">&#x000a0;No vs. yes</td><td align="left">0.60 (0.26&#x02013;1.39)</td><td char="." align="char">0.237</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left" colspan="5">Line of therapy</td></tr><tr><td align="left">&#x000a0;3 vs. &#x02265;4</td><td align="left">1.39 (0.66&#x02013;2.95)</td><td char="." align="char">0.386</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left" colspan="5">The most recent systemic therapy before EV</td></tr><tr><td align="left">&#x000a0;Chemotherapy vs. ICI</td><td align="left">0.61 (0.27&#x02013;1.38)</td><td char="." align="char">0.233</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left" colspan="5">Dose reduction/discontinuation</td></tr><tr><td align="left">&#x000a0;No vs. yes</td><td align="left">0.33 (0.13&#x02013;0.82)</td><td char="." align="char"><bold>0.017</bold></td><td char="&#x02013;" align="char">0.47 (0.18&#x02013;1.27)</td><td char="." align="char">0.139</td></tr><tr><td align="left" colspan="5">Prior radical therapy</td></tr><tr><td align="left">&#x000a0;No vs. yes</td><td align="left">0.77 (0.37&#x02013;1.60)</td><td char="." align="char">0.484</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left" colspan="5">TRSRs</td></tr><tr><td align="left">&#x000a0;No vs. yes</td><td align="left">0.33 (0.15&#x02013;0.72)</td><td char="." align="char"><bold>0.005</bold></td><td char="&#x02013;" align="char">0.45 (0.20&#x02013;1.05)</td><td char="." align="char">0.064</td></tr><tr><td align="left" colspan="5"><italic>PFS</italic></td></tr><tr><td align="left" colspan="5">Age</td></tr><tr><td align="left">&#x000a0;&#x02265;72 vs. &#x0003c;72</td><td align="left">1.25 (0.67&#x02013;2.35)</td><td char="." align="char">0.489</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left" colspan="5">Sex</td></tr><tr><td align="left">&#x000a0;Male vs. female</td><td align="left">1.10 (0.46&#x02013;2.64)</td><td char="." align="char">0.823</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left" colspan="5">ECOG PS</td></tr><tr><td align="left">&#x000a0;0&#x02013;1 vs. 2</td><td align="left">2.43 (1.02&#x02013;5.80)</td><td char="." align="char"><bold>0.046</bold></td><td char="&#x02013;" align="char">1.66 (0.67&#x02013;4.07)</td><td char="." align="char">0.272</td></tr><tr><td align="left" colspan="5">Bellmunt risk score<sup>a</sup></td></tr><tr><td align="left">&#x000a0;0&#x02013;1 vs. &#x02265;2</td><td align="left">1.48 (0.79&#x02013;2.76)</td><td char="." align="char">0.219</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left" colspan="5">Diabetes</td></tr><tr><td align="left">&#x000a0;No vs. yes</td><td align="left">1.16 (0.55&#x02013;2.44)</td><td char="." align="char">0.694</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left" colspan="5">Primary site</td></tr><tr><td align="left" colspan="5">&#x000a0;Bladder (ref)</td></tr><tr><td align="left">&#x000a0;&#x000a0;Upper urinary tract</td><td align="left">0.80 (0.39&#x02013;1.66)</td><td char="." align="char">0.555</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;&#x000a0;Bladder + upper urinary tract</td><td align="left">2.20 (0.88&#x02013;5.49)</td><td char="." align="char">0.091</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left" colspan="5">Metastatic site</td></tr><tr><td align="left">&#x000a0;LN vs. visceral</td><td align="left">1.05 (0.53&#x02013;2.11)</td><td char="." align="char">0.884</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left" colspan="5">Liver metastasis</td></tr><tr><td align="left">&#x000a0;No vs. yes</td><td align="left">0.90 (0.45&#x02013;1.79)</td><td char="." align="char">0.763</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left" colspan="5">Line of therapy</td></tr><tr><td align="left">&#x000a0;3 vs. &#x02265;4</td><td align="left">1.41 (0.74&#x02013;2.67)</td><td char="." align="char">0.291</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left" colspan="5">The most recent systemic therapy before EV</td></tr><tr><td align="left">&#x000a0;Chemotherapy vs ICI</td><td align="left">0.56 (0.27&#x02013;1.14)</td><td char="." align="char">0.108</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left" colspan="5">Dose reduction/discontinuation</td></tr><tr><td align="left">&#x000a0;No vs. yes</td><td align="left">0.38 (0.19&#x02013;0.77)</td><td char="." align="char"><bold>0.007</bold></td><td char="&#x02013;" align="char">0.54 (0.25&#x02013;1.15)</td><td char="." align="char">0.108</td></tr><tr><td align="left" colspan="5">Prior radical therapy</td></tr><tr><td align="left">&#x000a0;No vs. yes</td><td align="left">0.86 (0.46&#x02013;1.60)</td><td char="." align="char">0.634</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left" colspan="5">TRSRs</td></tr><tr><td align="left">&#x000a0;No vs. yes</td><td align="left">0.37 (0.19&#x02013;0.70)</td><td char="." align="char"><bold>0.003</bold></td><td char="&#x02013;" align="char">0.48 (0.24&#x02013;0.96)</td><td char="." align="char"><bold>0.039</bold></td></tr></tbody></table><table-wrap-foot><p><sup>&#x02020;</sup>Bellmunt risk score-liver metastases, hemoglobin level &#x0003c; 10g/dL, and ECOG PS &#x0003e; 0 are the factors; every point is added for each factor.</p><p><italic>CI</italic> confidence interval, <italic>HR</italic> hazard ratio, <italic>CSS</italic> cancer-specific survival, <italic>PFS</italic> progression-free survival, <italic>ECOG PS</italic> Eastern Cooperative Oncology Group performance status, <italic>EV</italic> enfortumab vedotin, <italic>ICI</italic> immune-checkpoint inhibitor, <italic>LN</italic> lymph node, <italic>TRSRs</italic> treatment-related skin reactions</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec12"><title>Comparison of survival between patients with and without dose reduction treatment discontinuation of EV</title><p id="Par22">The effect of dose reduction/discontinuation of EV due to any TRAEs was evaluated in all patients. Patients with or without dose reduction/discontinuation were compared, and patients&#x02019; characteristics are shown in Supplementary Table 2. The reception cycles of EV and the percentage of grade &#x02265;3 TRAEs were higher in the dose reduction/discontinuation group (median 6 cycles; IQR 4&#x02013;11 cycles vs. median 4 cycles; IQR 2&#x02013;7 cycles; <italic>p</italic> = 0.057, Grade &#x02265;3 TRAEs: 36.0% vs. 14.3%; <italic>p</italic> = 0.067), although the other variables were comparable between the groups. The Kaplan&#x02013;Meier curves for CSS and PFS are shown in Supplementary Figure 1, and the dose reduction/discontinuation group demonstrated significantly longer median survival (CSS: 15 [14&#x02013;NA] vs. 11 months&#x000a0;[7&#x02013;13]; <italic>p</italic> = 0.010, PFS: 10 [6&#x02013;NA] vs. 5 months&#x000a0;[3&#x02013;9] ;<italic> p</italic> = 0.003).</p><p id="Par23">We also evaluated how dose reduction/discontinuation due to TRSRs influenced survival outcomes. Patients with dose reduction/discontinuation due to TRSRs were also compared, and patients&#x02019; characteristics are shown in Supplementary Table 3. The EV cycles and the occurrence of grade 3 TRSRs were higher in the TRSRs group (median 10 cycles; IQR 6&#x02013;11 cycles vs. median 5 cycles; IQR 4&#x02013;9cycles; <italic>p</italic> = 0.097; Grade 3 TRSRs: 35.3% vs. 5.9%; <italic>p</italic> = 0.085). Regarding the other variables, similar characteristics were noted. The Kaplan&#x02013;Meier curves for CSS and PFS are shown in Supplementary Figure 2. The dose reduction/discontinuation group indicated longer survival than the non-reduction/discontinuation group (CSS: not reached [14&#x02013;NA] vs. 12 months [6&#x02013;NA]; <italic>p</italic> = 0.096, PFS: not reached [9&#x02013;NA] vs. 7 months [3&#x02013;NA];<italic> p</italic> = 0.020)</p></sec></sec><sec id="Sec13"><title>Discussion</title><p id="Par24">EV is a novel therapy for UC refractory to prior chemotherapy and ICIs, which targets nectin-4 expressed in UC [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. Nectin-4 is also expressed homogenously in normal skin keratinocytes and appendages. TRSRs are one of EV&#x02019;s most frequent AEs [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>], yet their association with EV survival and treatment response remains uncertain. We compared survival outcomes and treatment response to EV between those with and without TRSRs. The present study demonstrated that patients with TRSRs showed significantly longer CSS and PFS and superior ORR and suggested that susceptibility to EV is shared in skin and UC within an individual patient. Further, TRSRs may serve as a surrogate marker of treatment efficacy.</p><p id="Par25">A Japanese subgroup analysis of EV 301 and real-world data showed median OS and PFS of 10&#x02013;15 and 4&#x02013;7 months, respectively [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. ORR is reportedly 34.4%&#x02013;57.7% [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR16">16</xref>], similar to our study (although our cohort showed slightly higher ORR). Several Japanese studies have reported 29.4&#x02013;55.6% TRSR occurrences [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Similarly, approximately half of our patients experienced TRSRs.</p><p id="Par26">TRSRs typically occur relatively soon after EV initiation [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Eighty percent of TRSRs in the present cohort happened within the first three cycles, comparable to the previous studies. A study from a single center reported the association between treatment efficacy and TRSRs [<xref ref-type="bibr" rid="CR21">21</xref>]. The study also showed that the patients with TRSRs showed a significantly superior response (ORR 57.7% vs. 24.0%) [<xref ref-type="bibr" rid="CR21">21</xref>]. However, the researchers did not examine survival benefits. This was the pioneering study demonstrating an association between TRSRs and survival outcomes.</p><p id="Par27">The mechanism of TRSRs to EV has not been fully elucidated; however, there are two proposed mechanisms. One is the direct delivery of MMAE, which causes damage to normal tissue, such as the epidermis, due to its expression of nectin-4 [<xref ref-type="bibr" rid="CR4">4</xref>]. Another mechanism could be an allergy-related skin reaction, with type IV delayed hypersensitivity considered its pathology. This is believed to be linked to severe skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis [<xref ref-type="bibr" rid="CR22">22</xref>]. MMAE&#x02019;s direct effects are considered to be the leading cause of TRSRs.</p><p id="Par28">In addition, the pathophysiology of EV-related TRSRs has been assessed in several previous studies. Nectin-4, the target of EV, is typically expressed in the human skin [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Accordingly, the skin is likely to be affected by the pharmacological effect of EV. Furthermore, biopsy specimens of skin collected from the TRSR group demonstrated prominent ring and starburst mitoses and dyskeratosis within the epidermis, which reflect mitotic activity arrest [<xref ref-type="bibr" rid="CR24">24</xref>]. These findings were similar to those of taxane-induced toxic erythema [<xref ref-type="bibr" rid="CR25">25</xref>]. The MMAE of EV and taxanes is the microtubule inhibitor, which promotes the antitumor effect through mitosis inhibition and consequent apoptosis [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Therefore, this pharmacological mechanism of EV may be related to TRSRs as well as the antitumor effect.</p><p id="Par29">Similarly, TRSRs due to other antitumor agents have been previously reported as clinical indicators of treatment efficacy. For example, skin reactions related to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKI) for non-small cell lung cancer indicated treatment efficacy [<xref ref-type="bibr" rid="CR26">26</xref>]. Similar to nectin-4, EGFR is abundantly expressed in the keratinocytes in the epidermis and drives cell cycle activation and proliferation by activating downstream pathways [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Accordingly, EGFR-TKI affects keratinocytes and causes TRSRs by inducing growth arrest and apoptosis, which also promote antitumoral effects [<xref ref-type="bibr" rid="CR28">28</xref>]. Thus, TRSRs due to EGFR-TKI would be induced by the common pharmacological effect that acts in tumors, so the TRSRs could be a clinical indicator of therapeutic effect. In this perspective, EVs and EGFR-TKIs are similar in that their inherent pharmacological effects appear to arise from a common mechanism for AEs and antitumor effects. Therefore, this precedent would support the association between TRSRs and treatment response in EV.</p><p id="Par30">Regarding the association between other TRAEs of EV and treatment efficacy, several studies have reported that peripheral neuropathy (PN) was a favorable factor in survival outcomes [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. EV-related PN would be MMAE-mediated inhibition of microtubule-dependent axonal transport [<xref ref-type="bibr" rid="CR31">31</xref>]. However, PN has a relatively late onset, with a median of 15 weeks [<xref ref-type="bibr" rid="CR30">30</xref>]. Considering this, PN would be a dose-dependent AE, which could affect only responders to EV. Therefore, PN might be a consequent manifestation of sustained therapeutic effect rather than a predictive factor for treatment efficacy.</p><p id="Par31">One possible mechanism explaining the association between treatment response and TRSRs in an individual is genetic polymorphism. ATP binding cassette (ABC) transporter, which is encoded by the multidrug resistance (MDR) genes, promotes the efflux of MMAE [<xref ref-type="bibr" rid="CR32">32</xref>]. Of these transporters, many single nucleotide variants (SNVs) have been described, and some SNVs have reportedly affected prognosis and AEs in various cancer types [<xref ref-type="bibr" rid="CR32">32</xref>].</p><p id="Par32">For instance, the specific genotype of rs1045642 variant in <italic>MDR1</italic> was reportedly a favorable prognostic indicator for colorectal cancer treated with oxaliplatin [<xref ref-type="bibr" rid="CR33">33</xref>]. Regarding ADCs, <italic>MDR1</italic> upregulation was related to poor prognosis in patients with Hodgkin lymphoma who received brentuximab vedotin, an ADC for CD30 incorporated MMAE; however, it was not referred to as whether specific SNVs of ABC transporter regarding MMAE [<xref ref-type="bibr" rid="CR34">34</xref>]. Thus far, whether the specific variant of <italic>MDR</italic> for MMAE exists remains uncertain, and further investigation is needed.</p><p id="Par33">Furthermore, we evaluated how dose reduction/discontinuation of EV affects treatment efficacy. In this study, 37% of the patients (25/67) experienced dose reduction/discontinuation due to TRAEs. Among these patients, 68% (17/25) had TRSRs. Nevertheless, the dose reduction/discontinuation group demonstrated superior survival outcomes. A Japanese real-world study did not find a relationship between dose intensity and survival outcomes [<xref ref-type="bibr" rid="CR35">35</xref>]. Rather, several studies that have shown that even lower dose intensity due to PN revealed favorable survival outcomes and response [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. These results show that dose intensity may not influence survival outcomes.</p><p id="Par34">There are several limitations to the present study. First, it was retrospective and included a small number of patients. Second, there might be unrecognized confounding factors for survival outcomes, although we performed comprehensive analyses. Third, it was a multicenter study, and a central review regarding radiological evaluation was not performed. Finally, TRAEs were based on physicians&#x02019; reports, so there might be slight variances regarding grade evaluation. Considering these limitations, further investigation with a larger sample size would be needed to confirm the propriety of our results and verify our hypothesis.</p></sec><sec id="Sec14"><title>Conclusions</title><p id="Par35">In the present multicenter, retrospective study, the patients with TRSRs showed superior treatment response and more prolonged survival among those who received EV. TRSR might be a reasonable surrogate marker of treatment efficacy and predict good prognosis in the patients treated with EV.</p></sec><sec id="Sec15" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="10147_2024_2672_MOESM1_ESM.docx"><caption><p>Supplementary file1 (DOCX 240 KB)</p></caption></media></supplementary-material></p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We would like to thank Enago (<ext-link ext-link-type="uri" xlink:href="https://www.enago.jp/">https://www.enago.jp/</ext-link>) for proofreading our draft.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Conceptualization: Jun Nagayama; Data curation: Jun Nagayama, Satoshi Inoue, Hiroki Sai, Akira Hayakawa, Yuri Yuguchi, Tomohide Suzuki, Hirotaka Matsui, Takuma Yuba and Koya Morishita; Methodology: Jun Nagayama; Formal analysis and investigation: Jun Nagayama; Project administration: Satoshi Inoue; Writing-original draft preparation: Jun Nagayama; Writing-review and editing: Satoshi Inoue and Shusuke Akamatsu: Supervision: Shusuke Akamatsu.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding provided by Nagoya University.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data that support the findings of this study are available on request from the corresponding author, Jun Nagayama. The data are not publicly available due to the containing information that could compromise the privacy of research participants.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par36">Shusuke Akamatsu received honoraria for lectures from Astellas. The remaining authors have declared no conflict of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Powles</surname><given-names>T</given-names></name><name><surname>Rosenberg</surname><given-names>JE</given-names></name><name><surname>Sonpavde</surname><given-names>GP</given-names></name><etal/></person-group><article-title>Enfortumab vedotin in previously treated advanced urothelial carcinoma</article-title><source>N Engl J Med</source><year>2021</year><volume>384</volume><fpage>1125</fpage><lpage>1135</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2035807</pub-id><pub-id pub-id-type="pmid">33577729</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Powles T, Rosenberg JE, Sonpavde GP et al (2021) Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 384:1125&#x02013;1135<pub-id pub-id-type="pmid">33577729</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>E</given-names></name><name><surname>Weinstock</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group><article-title>FDA approval summary: enfortumab vedotin for locally advanced or metastatic urothelial carcinoma</article-title><source>Clin Cancer Res</source><year>2021</year><volume>27</volume><fpage>922</fpage><lpage>927</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-20-2275</pub-id><pub-id pub-id-type="pmid">32962979</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Chang E, Weinstock C, Zhang L et al (2021) FDA approval summary: enfortumab vedotin for locally advanced or metastatic urothelial carcinoma. Clin Cancer Res 27:922&#x02013;927<pub-id pub-id-type="pmid">32962979</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Challita-Eid</surname><given-names>PM</given-names></name><name><surname>Satpayev</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><etal/></person-group><article-title>Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models</article-title><source>Cancer Res</source><year>2016</year><volume>76</volume><fpage>3003</fpage><lpage>3013</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-1313</pub-id><pub-id pub-id-type="pmid">27013195</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Challita-Eid PM, Satpayev D, Yang P et al (2016) Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res 76:3003&#x02013;3013<pub-id pub-id-type="pmid">27013195</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Lacouture</surname><given-names>ME</given-names></name><name><surname>Patel</surname><given-names>AB</given-names></name><name><surname>Rosenberg</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Management of dermatologic events associated with the nectin-4-directed antibody-drug conjugate enfortumab vedotin</article-title><source>Oncologist</source><year>2022</year><volume>27</volume><fpage>e223</fpage><lpage>e232</lpage><pub-id pub-id-type="doi">10.1093/oncolo/oyac001</pub-id><pub-id pub-id-type="pmid">35274723</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Lacouture ME, Patel AB, Rosenberg JE et al (2022) Management of dermatologic events associated with the nectin-4-directed antibody-drug conjugate enfortumab vedotin. Oncologist 27:e223&#x02013;e232<pub-id pub-id-type="pmid">35274723</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Rikitake</surname><given-names>Y</given-names></name><name><surname>Mandai</surname><given-names>K</given-names></name><name><surname>Takai</surname><given-names>Y</given-names></name></person-group><article-title>The role of nectins in different types of cell-cell adhesion</article-title><source>J Cell Sci</source><year>2012</year><volume>125</volume><fpage>3713</fpage><lpage>3722</lpage><pub-id pub-id-type="doi">10.1242/jcs.099572</pub-id><pub-id pub-id-type="pmid">23027581</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Rikitake Y, Mandai K, Takai Y (2012) The role of nectins in different types of cell-cell adhesion. J Cell Sci 125:3713&#x02013;3722<pub-id pub-id-type="pmid">23027581</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Sanders</surname><given-names>C</given-names></name><name><surname>Lau</surname><given-names>JF</given-names></name><name><surname>Dietrich</surname><given-names>D</given-names></name><etal/></person-group><article-title>Nectin-4 is widely expressed in head and neck squamous cell carcinoma</article-title><source>Oncotarget.</source><year>2022</year><volume>13</volume><fpage>1166</fpage><lpage>1173</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.28299</pub-id><pub-id pub-id-type="pmid">36268557</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Sanders C, Lau JF, Dietrich D et al (2022) Nectin-4 is widely expressed in head and neck squamous cell carcinoma. Oncotarget. 13:1166&#x02013;1173<pub-id pub-id-type="pmid">36268557</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Sethy</surname><given-names>C</given-names></name><name><surname>Goutam</surname><given-names>K</given-names></name><name><surname>Nayak</surname><given-names>D</given-names></name><etal/></person-group><article-title>Clinical significance of a pvrl 4 encoded gene Nectin-4 in metastasis and angiogenesis for tumor relapse</article-title><source>J Cancer Res Clin Oncol</source><year>2020</year><volume>146</volume><fpage>245</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1007/s00432-019-03055-2</pub-id><pub-id pub-id-type="pmid">31617074</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Sethy C, Goutam K, Nayak D et al (2020) Clinical significance of a pvrl 4 encoded gene Nectin-4 in metastasis and angiogenesis for tumor relapse. J Cancer Res Clin Oncol 146:245&#x02013;259<pub-id pub-id-type="pmid">31617074</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Tomiyama</surname><given-names>E</given-names></name><name><surname>Fujita</surname><given-names>K</given-names></name><name><surname>Rodriguez Pena</surname><given-names>MDC</given-names></name><etal/></person-group><article-title>Expression of nectin-4 and PD-L1 in upper tract urothelial carcinoma</article-title><source>Int J Mol Sci.</source><year>2020</year><volume>21</volume><fpage>5390</fpage><pub-id pub-id-type="doi">10.3390/ijms21155390</pub-id><pub-id pub-id-type="pmid">32751328</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Tomiyama E, Fujita K, Rodriguez Pena MDC et al (2020) Expression of nectin-4 and PD-L1 in upper tract urothelial carcinoma. Int J Mol Sci. 21:5390<pub-id pub-id-type="pmid">32751328</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Minato</surname><given-names>A</given-names></name><name><surname>Kimuro</surname><given-names>R</given-names></name><name><surname>Ohno</surname><given-names>D</given-names></name><etal/></person-group><article-title>Efficacy and tolerability of enfortumab vedotin for metastatic urothelial carcinoma: early experience in the real world</article-title><source>Anticancer Res</source><year>2023</year><volume>43</volume><fpage>4055</fpage><lpage>4060</lpage><pub-id pub-id-type="doi">10.21873/anticanres.16594</pub-id><pub-id pub-id-type="pmid">37648337</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Minato A, Kimuro R, Ohno D et al (2023) Efficacy and tolerability of enfortumab vedotin for metastatic urothelial carcinoma: early experience in the real world. Anticancer Res 43:4055&#x02013;4060<pub-id pub-id-type="pmid">37648337</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Seagen Inc., Astellas Pharma US, Inc. (2021) Padcev (enfortumab vedotinejfv) for injection [prescribing information]. Accessed 13 July 2021.</mixed-citation></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Uemura</surname><given-names>K</given-names></name><name><surname>Ito</surname><given-names>H</given-names></name><name><surname>Jikuya</surname><given-names>R</given-names></name><etal/></person-group><article-title>Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data</article-title><source>Int J Urol</source><year>2024</year><volume>31</volume><fpage>678</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1111/iju.15437</pub-id><pub-id pub-id-type="pmid">38402449</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Uemura K, Ito H, Jikuya R et al (2024) Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data. Int J Urol 31:678&#x02013;684<pub-id pub-id-type="pmid">38402449</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Eisenhauer</surname><given-names>EA</given-names></name><name><surname>Therasse</surname><given-names>P</given-names></name><name><surname>Bogaerts</surname><given-names>J</given-names></name><etal/></person-group><article-title>New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)</article-title><source>Eur J Cancer</source><year>2009</year><volume>45</volume><fpage>228</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2008.10.026</pub-id><pub-id pub-id-type="pmid">19097774</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228&#x02013;247<pub-id pub-id-type="pmid">19097774</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Bellmunt</surname><given-names>J</given-names></name><name><surname>Chouriri</surname><given-names>TK</given-names></name><name><surname>Fourgeray</surname><given-names>R</given-names></name><etal/></person-group><article-title>Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><fpage>1850</fpage><lpage>1855</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.25.4599</pub-id><pub-id pub-id-type="pmid">20231682</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Bellmunt J, Chouriri TK, Fourgeray R et al (2010) Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 28:1850&#x02013;1855<pub-id pub-id-type="pmid">20231682</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">National Cancer Institute. Cancer Therapy Evaluation Program: Protocol Development: Common Terminology Criteria for Adverse Events (CTCAE) v5.0. <ext-link ext-link-type="uri" xlink:href="https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50">https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50</ext-link> Accessed 27 November 2017.</mixed-citation></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Kanda</surname><given-names>Y</given-names></name></person-group><article-title>Investigation of the freely available easy-to-use software 'EZR' for medical statistics</article-title><source>Bone Marrow Transplant</source><year>2013</year><volume>48</volume><fpage>452</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1038/bmt.2012.244</pub-id><pub-id pub-id-type="pmid">23208313</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Kanda Y (2013) Investigation of the freely available easy-to-use software &#x0201c;EZR&#x0201d; for medical statistics. Bone Marrow Transplant 48:452&#x02013;458<pub-id pub-id-type="pmid">23208313</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Matsubara</surname><given-names>N</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Japanese subgroup analysis of EV-301: an open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma</article-title><source>Cancer Med</source><year>2023</year><volume>12</volume><fpage>2761</fpage><lpage>2771</lpage><pub-id pub-id-type="doi">10.1002/cam4.5165</pub-id><pub-id pub-id-type="pmid">36052536</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Matsubara N, Takahashi M, Kobayashi K et al (2023) Japanese subgroup analysis of EV-301: an open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma. Cancer Med 12:2761&#x02013;2771<pub-id pub-id-type="pmid">36052536</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Hara</surname><given-names>T</given-names></name><name><surname>Matsushita</surname><given-names>Y</given-names></name><name><surname>Harada</surname><given-names>K</given-names></name><etal/></person-group><article-title>Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: a retrospective multicenter study in Japan</article-title><source>Int J Urol</source><year>2024</year><volume>31</volume><fpage>696</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1111/iju.15435</pub-id><pub-id pub-id-type="pmid">38424707</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Hara T, Matsushita Y, Harada K et al (2024) Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: a retrospective multicenter study in Japan. Int J Urol 31:696&#x02013;698<pub-id pub-id-type="pmid">38424707</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Uemura</surname><given-names>M</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><etal/></person-group><article-title>A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma</article-title><source>Invest New Drugs</source><year>2020</year><volume>38</volume><fpage>1056</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1007/s10637-019-00844-x</pub-id><pub-id pub-id-type="pmid">31444589</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Takahashi S, Uemura M, Kimura T et al (2020) A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma. Invest New Drugs 38:1056&#x02013;1066<pub-id pub-id-type="pmid">31444589</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>EY</given-names></name><name><surname>Petrylak</surname><given-names>DP</given-names></name><name><surname>O&#x02019;Donnell</surname><given-names>PH</given-names></name><etal/></person-group><article-title>Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial</article-title><source>Lancet Oncol</source><year>2021</year><volume>22</volume><fpage>872</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(21)00094-2</pub-id><pub-id pub-id-type="pmid">33991512</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Yu EY, Petrylak DP, O&#x02019;Donnell PH et al (2021) Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. Lancet Oncol 22:872&#x02013;882<pub-id pub-id-type="pmid">33991512</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>JE</given-names></name><name><surname>O'Donnell</surname><given-names>PH</given-names></name><name><surname>Balar</surname><given-names>AV</given-names></name><etal/></person-group><article-title>Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy</article-title><source>J Clin Oncol</source><year>2019</year><volume>37</volume><fpage>2592</fpage><lpage>2600</lpage><pub-id pub-id-type="doi">10.1200/JCO.19.01140</pub-id><pub-id pub-id-type="pmid">31356140</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Rosenberg JE, O&#x02019;Donnell PH, Balar AV et al (2019) Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol 37:2592&#x02013;2600<pub-id pub-id-type="pmid">31356140</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Vlachou</surname><given-names>E</given-names></name><name><surname>Matoso</surname><given-names>A</given-names></name><name><surname>McConkey</surname><given-names>D</given-names></name><etal/></person-group><article-title>Enfortumab vedotin-related cutaneous toxicity and radiographic response in patients with urothelial cancer: a single-center experience and review of the literature</article-title><source>Eur Urol Open Sci</source><year>2023</year><volume>49</volume><fpage>100</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.euros.2023.01.002</pub-id><pub-id pub-id-type="pmid">36820243</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Vlachou E, Matoso A, McConkey D et al (2023) Enfortumab vedotin-related cutaneous toxicity and radiographic response in patients with urothelial cancer: a single-center experience and review of the literature. Eur Urol Open Sci 49:100&#x02013;103<pub-id pub-id-type="pmid">36820243</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Duong</surname><given-names>TA</given-names></name><name><surname>Valeyrie-Allanore</surname><given-names>L</given-names></name><name><surname>Wolkenstein</surname><given-names>P</given-names></name><etal/></person-group><article-title>Severe cutaneous adverse reactions to drugs</article-title><source>Lancet</source><year>2017</year><volume>390</volume><fpage>1996</fpage><lpage>2011</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)30378-6</pub-id><pub-id pub-id-type="pmid">28476287</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Duong TA, Valeyrie-Allanore L, Wolkenstein P et al (2017) Severe cutaneous adverse reactions to drugs. Lancet 390:1996&#x02013;2011<pub-id pub-id-type="pmid">28476287</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Murata</surname><given-names>M</given-names></name><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><etal/></person-group><article-title>NECTIN4 expression in extramammary paget&#x02019;s disease: implication of a new therapeutic target</article-title><source>Int J Mol Sci.</source><year>2020</year><volume>21</volume><fpage>5891</fpage><pub-id pub-id-type="doi">10.3390/ijms21165891</pub-id><pub-id pub-id-type="pmid">32824340</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Murata M, Ito T, Tanaka Y et al (2020) NECTIN4 expression in extramammary paget&#x02019;s disease: implication of a new therapeutic target. Int J Mol Sci. 21:5891<pub-id pub-id-type="pmid">32824340</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Hirotsu</surname><given-names>KE</given-names></name><name><surname>Rana</surname><given-names>J</given-names></name><name><surname>Wnag</surname><given-names>JY</given-names></name><etal/></person-group><article-title>Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma</article-title><source>J Am Acad Dermatol</source><year>2021</year><volume>85</volume><fpage>1610</fpage><lpage>1611</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2020.11.067</pub-id><pub-id pub-id-type="pmid">33301805</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Hirotsu KE, Rana J, Wnag JY et al (2021) Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma. J Am Acad Dermatol 85:1610&#x02013;1611<pub-id pub-id-type="pmid">33301805</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Prieto-Torres</surname><given-names>L</given-names></name><name><surname>Llamas-Velasco</surname><given-names>M</given-names></name><name><surname>Machan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Taxanes-induced cutaneous eruption: another histopathologic mimicker of malignancy</article-title><source>J Eur Acad Dermatol Venereol</source><year>2016</year><volume>30</volume><fpage>638</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1111/jdv.13475</pub-id><pub-id pub-id-type="pmid">26558745</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Prieto-Torres L, Llamas-Velasco M, Machan S et al (2016) Taxanes-induced cutaneous eruption: another histopathologic mimicker of malignancy. J Eur Acad Dermatol Venereol 30:638&#x02013;644<pub-id pub-id-type="pmid">26558745</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>HB</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Lv</surname><given-names>TF</given-names></name><etal/></person-group><article-title>Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e55128</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0055128</pub-id><pub-id pub-id-type="pmid">23383079</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Liu HB, Wu Y, Lv TF et al (2013) Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 8:e55128<pub-id pub-id-type="pmid">23383079</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Mendelsohn</surname><given-names>J</given-names></name><name><surname>Baselga</surname><given-names>J</given-names></name></person-group><article-title>Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer</article-title><source>J Clin Oncol</source><year>2003</year><volume>21</volume><fpage>2787</fpage><lpage>2799</lpage><pub-id pub-id-type="doi">10.1200/JCO.2003.01.504</pub-id><pub-id pub-id-type="pmid">12860957</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21:2787&#x02013;2799<pub-id pub-id-type="pmid">12860957</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Lacouture</surname><given-names>ME</given-names></name></person-group><article-title>Mechanisms of cutaneous toxicities to EGFR inhibitors</article-title><source>Nat Rev Cancer</source><year>2006</year><volume>6</volume><fpage>803</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1038/nrc1970</pub-id><pub-id pub-id-type="pmid">16990857</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6:803&#x02013;812<pub-id pub-id-type="pmid">16990857</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Hayakawa</surname><given-names>N</given-names></name><name><surname>Kikuchi</surname><given-names>E</given-names></name><name><surname>Kaneko</surname><given-names>G</given-names></name><etal/></person-group><article-title>Association between response to enfortumab vedotin and peripheral neuropathy in urothelial carcinoma patients: a multicenter retrospective study</article-title><source>Jpn J Clin Oncol</source><year>2024</year><pub-id pub-id-type="doi">10.1093/jjco/hyae082</pub-id><pub-id pub-id-type="pmid">38943559</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Hayakawa N, Kikuchi E, Kaneko G et al (2024) Association between response to enfortumab vedotin and peripheral neuropathy in urothelial carcinoma patients: a multicenter retrospective study. Jpn J Clin Oncol. 10.1093/jjco/hyae082<pub-id pub-id-type="pmid">38943559</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Taoka</surname><given-names>R</given-names></name><name><surname>Kamada</surname><given-names>M</given-names></name><name><surname>Izumi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study</article-title><source>Int J Clin Oncol</source><year>2024</year><volume>29</volume><fpage>602</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1007/s10147-024-02481-8</pub-id><pub-id pub-id-type="pmid">38418804</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Taoka R, Kamada M, Izumi K et al (2024) Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study. Int J Clin Oncol 29:602&#x02013;611<pub-id pub-id-type="pmid">38418804</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Best</surname><given-names>RL</given-names></name><name><surname>LaPointe</surname><given-names>NE</given-names></name><name><surname>Azarenko</surname><given-names>O</given-names></name><etal/></person-group><article-title>Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy</article-title><source>Toxicol Appl Pharmacol</source><year>2021</year><volume>421</volume><fpage>115534</fpage><pub-id pub-id-type="doi">10.1016/j.taap.2021.115534</pub-id><pub-id pub-id-type="pmid">33852878</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Best RL, LaPointe NE, Azarenko O et al (2021) Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy. Toxicol Appl Pharmacol 421:115534<pub-id pub-id-type="pmid">33852878</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Juan-Carlos</surname><given-names>PM</given-names></name><name><surname>Herrera</surname><given-names>F</given-names></name><name><surname>Blanco</surname><given-names>A</given-names></name><etal/></person-group><article-title>ABC transporter superfamily. An updated overview, relevance in cancer multidrug resistance and perspectives with personalized medicine</article-title><source>Mol Biol Rep</source><year>2021</year><volume>48</volume><fpage>1883</fpage><lpage>1901</lpage><pub-id pub-id-type="doi">10.1007/s11033-021-06155-w</pub-id><pub-id pub-id-type="pmid">33616835</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Juan-Carlos PM, Herrera F, Blanco A et al (2021) ABC transporter superfamily. An updated overview, relevance in cancer multidrug resistance and perspectives with personalized medicine. Mol Biol Rep 48:1883&#x02013;1901<pub-id pub-id-type="pmid">33616835</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Kang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Association of ABCB1 genetic polymorphisms with susceptibility to colorectal cancer and therapeutic prognosis</article-title><source>Pharmacogenomics</source><year>2013</year><volume>14</volume><fpage>897</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.2217/pgs.13.78</pub-id><pub-id pub-id-type="pmid">23746184</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Wu H, Kang H, Liu Y et al (2013) Association of ABCB1 genetic polymorphisms with susceptibility to colorectal cancer and therapeutic prognosis. Pharmacogenomics 14:897&#x02013;911<pub-id pub-id-type="pmid">23746184</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>O'Donnell</surname><given-names>PH</given-names></name><etal/></person-group><article-title>CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin</article-title><source>Mol Cancer Ther</source><year>2015</year><volume>14</volume><fpage>1376</fpage><lpage>1384</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-15-0036</pub-id><pub-id pub-id-type="pmid">25840583</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Chen R, Gupta S, O&#x02019;Donnell PH et al (2015) CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol Cancer Ther 14:1376&#x02013;1384<pub-id pub-id-type="pmid">25840583</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Miyake</surname><given-names>M</given-names></name><name><surname>Nishimura</surname><given-names>N</given-names></name><name><surname>Oda</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from multicenter real-world Japanese cohort</article-title><source>Jpn J Clin Oncol</source><year>2024</year><volume>54</volume><fpage>329</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1093/jjco/hyad170</pub-id><pub-id pub-id-type="pmid">38061911</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Miyake M, Nishimura N, Oda Y et al (2024) Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from multicenter real-world Japanese cohort. Jpn J Clin Oncol 54:329&#x02013;338<pub-id pub-id-type="pmid">38061911</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>